Bristol Myers Squibb shares were falling Thursday despite a first-quarter financial report that beat expectations amid ...

Bristol Myers Squibb & Co (NYSE:BMY) reported first-quarter 2025 revenues of $11.20 billion, beating the consensus of $10.70 ...

Bristol Myers Squibb reported higher-than-expected first-quarter revenue on Thursday and raised its full-year forecast due to ...

On the heels of a clinical setback for Bristol Myers Squibb’s schizophrenia newcomer Cobenfy, the New Jersey pharma is ...

The pharmaceutical company on Thursday said it raised its full-year guidance for revenue in the year to a range of $45.8 billion to $46.8 billion, up from a previous forecast of $45.5 billion.

The stock's rise snapped a four-day losing streak.

Bristol-Myers Squibb (BMY) stock is down 11% year-to-date as the company navigates several looming patent cliffs. After a $13 ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $58.71, a high ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

Merck, Bristol Myers Squibb, Sanofi and Roche had little clarity on the potential impact of President Donald Trump’s ...

Over the past five years, it posted a negative one-day return in 55% of cases, with a median drop of 3.0% and a maximum ...

Sales of the company's cancer immunotherapy Opdivo were $2.3 billion in the quarter, compared with Wall Street forecasts of ...